New hope for liver cancer: drug combo trial launches

NCT ID NCT05441475

ENROLLING_BY_INVITATION Disease control Sponsor: Abbisko Therapeutics Co, Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new drug, ABSK-011, combined with the immunotherapy atezolizumab (or standard care) in 118 people with advanced or unresectable hepatocellular carcinoma, a type of liver cancer. The study aims to see if the combination is safe and can shrink tumors. Participants must have a specific genetic marker (FGF19 overexpression) and have not had prior systemic therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABSK-011 (a targeted cancer drug) combined with atezolizumab (an immunotherapy) or standard care
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced liver cancer that has not responded to other therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply to everyone. Side effects from the drug combination could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Hubei, Shanghai Municipality, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.